Streetbeat News

Price Targets

PLRX

Pliant Therapeutics' stock price is trading lower following HC Wainwright's decision to maintain a Buy rating but reduce its price target from $52 to $48.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:39 pm

REGN

RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $1076 to $1110.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:35 pm

RGA

RBC Capital analyst Scott Heleniak has maintained an Outperform rating on Reinsurance Group of America (RGA) and increased the price target from $170 to $185.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:30 pm

LYB

RBC Capital analyst Arun Viswanathan has reiterated an Outperform rating on LyondellBasell Industries (NYSE:LYB), maintaining a price target of $107.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:27 pm

XOM

RBC Capital analyst Biraj Borkhataria reiterates a 'Sector Perform' rating on Exxon Mobil (XOM) and maintains a $120 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:23 pm

CMS

RBC Capital analyst Shelby Tucker maintains a Sector Perform rating on CMS Energy (NYSE:CMS) and raises the price target from $64 to $65.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:20 pm

CPT

RBC Capital analyst Brad Heffern has reiterated an Outperform rating on Camden Prop Trust (NYSE:CPT) and maintained a $103 price target. This reaffirms the analyst's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:17 pm

CVX

RBC Capital analyst Biraj Borkhataria maintains an Outperform rating on Chevron (CVX) and raises the price target from $185 to $190.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:14 pm

CHD

RBC Capital analyst Nik Modi maintains a Sector Perform rating on Church & Dwight Co (NYSE:CHD) and raises the price target from $94 to $103.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:12 pm

BSX

RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Boston Scientific (NYSE:BSX) and maintained a $70 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:06 pm